O
ONK Therapeutics
Pioneering optimally engineered NK cell therapies to cure patients with cancer
About ONK Therapeutics
ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignancies and solid tumors. The Company was founded in 2015, by Prof. O’Dwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumour microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumour antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This promising new approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor specific antigen) and extrinsic (e.g. signalling through the death receptor pathway) apoptotic pathways, and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen independent TRAILv.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Galway, Ireland
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 67.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Cellular, Spinout, Biotech and Pharma, Cell Therapy, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jan 2022 | $22M | $86M | Cormorant Asset Management · Acorn Bioventures · Enterprise Ireland · ALSHC | ↗ |
| EARLY VC✓Equity / VC | Oct 2020 | $8M | $32M | Seamus Mulligan · Acorn Bioventures | — |
Growth signals
Latest recorded traffic for ONK Therapeutics is 1.3K monthly website visits, down 55.2% over the last three months. ONK Therapeutics's team declined 6.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ONK Therapeutics in the Galway ecosystem
The ONK Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
- SMSeamus Mulligan
Acorn Bioventures
ALSHC
Cormorant Asset Management
Enterprise Ireland
Other known investors1 additional known investor
University of Galway
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ONK Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ONK Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










